INFO & CONTACTS:  +39 02 2390 1

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

Phase: Phase I-II clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Ematologia

Drug: AZD4512 (CD22 β-glu exatecan)

Pathologies: Hematologic malignancies (Lymphomas, Leukemias, Myelomas, and others)

ClinicalTrials.gov: Read more about clinical trials

Despite the therapeutic advances in B-NHL over the past decade, there are significant unmet needs for new safe and effective therapies for patients with relapsed or refractory (R/R) B-NHL whose disease is no longer responsive to standard therapies. 

Cluster of differentiation 22 (CD22) is a transmembrane protein with a B-cell restricted expression, including various B-NHL subtypes. CD22 targeting by Chimeric antigen receptor (CAR)-T cells and antibody-drug conjugate (ADCs) have demonstrated clinical activity in B-NHL, however, no therapies have been granted approval for this indication. ADCs targeting CD22 in particular have been limited by payload driven toxicity. AZD4512 is a CD22-directed ADC consisting of 3 components: 1) the recombinant human immunoglobulin class G subtype 1 kappa antibody, specific for CD22, 2) the exatecan payload (“AZ14027588”) that causes cell death by binding to and inhibiting topoisomerase 1 (TOP1i), an enzyme necessary to relax deoxyribonucleic acid (DNA) supercoils during replication and transcription, and 3) a β-glucuronidase-cleavable linker composed of isomannide-polyethylene glycol, β-glucuronide benzyl amine and a maleamide linker that covalently attaches exatecan to the anti-CD22 monoclonal antibody. AZD4512 improves upon previous CD22 targeting ADCs through use of a novel linker and payload giving a potentially wider therapeutic index. 

This study is modular in design, allowing initial assessment of the safety, tolerability, and efficacy in multiple treatment arms. Module 1 is designed to evaluate the safety, tolerability, and efficacy of AZD4512 monotherapy, at increasing doses in participants with R/R B-cell NHL. The study will also characterize PK and immunogenicity and explore potential biological activity by assessing pharmacodynamic (PD), exploratory biomarkers and anti-tumor activity. Further modules studying AZD4512 as monotherapy in expansions or in combination with other anticancer agents will be

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe